Bayer’s Investor Forum Unfolds Against CEO Warnings and a Looming Supreme Court Date

Bayer shares end Friday at €35.95, barely above 200-day MA, as CEO Anderson warns of Hormuz disruption risks and Germany's high costs. Q1 results show mixed divisional performance.

Bayer’s management faces a packed agenda this week. While the group plays host to private shareholders at the DSW investor forum in Essen this evening, CEO Bill Anderson has simultaneously cranked up the pressure with an unusually blunt interview, warning of fallout from Hormuz and decrying Germany’s cost structure. The twin narratives — one a bid for retail confidence, the other a reality check from the corner office — leave the stock treading a narrow technical line.

The shares ended Friday at €35.95, a daily gain of 1.58% that failed to erase the week’s losses. On a seven-day view Bayer fell 1.45%, and over the past month the decline amounts to 2.79%. The year-to-date performance is also negative, down 5.46%, though over twelve months the stock has rallied 35.07%. The distance to the 200-day moving average, at €35.80, is a razor-thin 0.41% — a level that offers neither clear support nor convincing upward momentum.

Q1 numbers still dominate the conversation

Operationally, Bayer entered this period on solid footing. First-quarter 2026 revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.405 billion. EBITDA before special items climbed to €4.453 billion, while adjusted earnings per share advanced 12.9% to €2.71. The company reaffirmed its full-year currency-adjusted guidance, including revenue of €44.5–46.5 billion and adjusted EPS of €4.10–4.60.

But the performance across divisions is uneven. Crop Science, the agricultural unit, provided the strongest lift, with organic sales up 6.8% to €7.558 billion and segment EBITDA jumping 17.9%. Pharmaceuticals, however, remained a drag: revenue was flat at €4.249 billion and EBITDA before special items slipped 7.5% to €1.242 billion. Consumer Health grew revenue 5.3% to €1.491 billion but saw EBITDA fall to €337 million. That mix of strengths and weaknesses will surely colour the Q&A at the ATLANTIC Congress Hotel, where the forum runs from 18:30 to 20:45.

Anderson’s warnings add a geopolitical layer

The CEO’s interview, published June 5, introduced another dimension of risk. Around one-third of global nitrogen-based fertiliser trade transits the Strait of Hormuz, Anderson told t-online. If the blockage persists, harvests in the northern hemisphere could be significantly reduced by autumn. Less grain means less purchasing power for farmers — and less demand for the seeds that form the core of Bayer’s agricultural business. A weaker Crop Science division would be a direct blow to the group’s current growth engine.

Anderson did not stop there. He launched a sharp critique of Germany’s competitiveness, noting that electricity prices are more than three times those on the Texas Gulf Coast and double those in China. High non-wage labour costs and rising bureaucratic burdens compound the disadvantage. He acknowledged speaking with Chancellor Merz but saw no immediate relief, warning that additional reporting obligations and regulation are piling up. These structural headwinds keep Bayer’s cost base under persistent pressure, independent of the geopolitical turmoil.

The Supreme Court date that could change the math

The most decisive catalyst, however, comes from the courtroom. According to JPMorgan, the US Supreme Court is expected to rule on the glyphosate litigation complex before the end of June, with an initial Opinion Day already scheduled for June 11. Roughly 80% of the remaining cases against Bayer would be affected by that decision. A ruling favourable to the company could lift the stock far beyond the narrow band it currently occupies, while an adverse outcome would deepen uncertainty.

For now, the investor evening in Essen offers the immediate forum for management to defend the outlook — especially the strength in Crop Science and the path to stabilising Pharma. But Anderson’s two-pronged warning from the interview, combined with the legal cliffhanger, means any reassurance will be tested before the week is out.